Lentigo maligna and radiotherapy. by Wilson, L.D.
T h e  n e w  e ng l a nd  j o u r na l  o f  m e dic i n e
n engl j med 354;12 www.nejm.org march 23, 20061322
Lentigo Maligna and Radiotherapy
To the Editor: Imiquimod has recently been 
shown to be effective in the management of len-
tigo maligna, as demonstrated in Images in Clin-
ical Medicine (Nov. 17 issue)1 and in other reports. 
The authors correctly suggest that imiquimod may 
be effective for lentigo maligna, but readers are 
subsequently led to believe that perhaps this is 
the only alternative to surgery. Although imiqui-
mod may be a promising nonsurgical alternative 
for the treatment of lentigo maligna, radiothera-
py has been clinically successful, with excellent 
cosmesis. In one series of 101 patients with ei-
ther lentigo maligna or lentigo maligna melanoma 
who were treated with radiotherapy and followed 
for a minimum of 2 years (mean, 8 years), the 
mean time to recurrence was 45.6 months, with 
a recurrence rate of 7 percent.2 Although radio-
therapy may not be as convenient as treatment with 
a self-administered topical agent, it should be 
recognized as a potential therapeutic choice for 
patients with lentigo maligna. Radiotherapy can 
provide excellent cosmesis and local control.
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the author replies: I agree with Dr. Wilson 
that radiotherapy is the most effective nonsurgi-
cal treatment for lentigo maligna.1 However, im-
iquimod is an emerging new treatment that has 
many advantages. It can be administered by the 
patient, reducing the cost of treatment. Side ef-
fects, such as skin irritation, are transient and 
resolve spontaneously after treatment, leaving no 
scars or skin marks. By contrast, radiotherapy may 
induce chronic radiodermatitis and, sometimes, 
skin cancer.2 Imiquimod not only stimulates the 
immune system but also inhibits angiogenesis, a 
fact that contributes to its clinical efficacy against 
different types of dermatologic conditions such as 
genital warts, actinic keratoses, lentigo maligna, 
basal-cell carcinoma, and squamous-cell carci-
noma.3
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Treatment for Rheumatic Disorders
To the Editor: With regard to the letter by Dr. 
April (Oct. 6 issue),1 in reference to a Perspective 
article by Topol on the overuse of nesiritide for 
congestive heart failure (July 14 issue)2: Dr. April 
claims that the current president of the American 
College of Rheumatology (ACR), along with an 
unnamed past president, encouraged the use of 
intravenous office infusion of infliximab (Remi-
cade) over other treatments, such as self-injected 
medications, “as a way to offset poor reimburse-
ment for patient care.” We are writing to respond 
to Dr. April’s unfounded statements.
The issue of access to medications for the treat-
ment of rheumatoid arthritis and other autoim-
mune diseases came into focus with the devel-
opment of new biologic treatments that are 
administered only by self-injection or as intrave-
nous infusions. At the time that these treatments 
were introduced, Medicare did not cover self-
injected medications, which forced many patients 
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to choose infusions administered in hospitals or 
in physicians’ offices. Since 2002, the ACR has 
advocated that patients should have access to all 
approved therapies for rheumatic disease and 
that decisions about which treatment is most ap-
propriate should be made by patients and their 
physicians. The ACR has also clearly stated that 
rheumatologists should be compensated for the 
work that they do and not for the drugs that they 
choose. We believe that the only factor that should 
influence a physician’s decision regarding which 
medication to prescribe is the best interest of the 
patient.
The ACR leadership, including the current 
president (Dr. Tindall), fought for the inclusion 
of self-injectable medications in the 2003 Medi-
care Replacement Drug Demonstration Project 
and worked hard to encourage rheumatologists 
to help their patients participate in this project. 
As of October 7, 2005, 40,239 patients were en-
rolled, with coverage for self-injected medica-
tions, including 14,337 patients with rheumatoid 
arthritis. Neither the ACR nor its president has 
ever encouraged physicians to favor office infu-
sions over other treatments for rheumatic dis-
eases.
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Antibodies Neutralizing Peginterferon Alfa during Retreatment 
of Hepatitis C
To the Editor: Peginterferons are widely used 
to treat chronic hepatitis C virus (HCV) infection, 
an important cause of liver cirrhosis and hepato-
cellular carcinoma.1-4 We describe a patient who 
did not have a virologic response to peginterfer-
on and had a virtual absence of circulating pe-
ginterferon alfa-2a but had neutralizing antibod-
ies against interferon alfa.
A 38-year-old man with liver cirrhosis (Child–
Pugh class A; score, 5) was referred to our hos-
pital for evaluation of his chronic HCV infection. 
He had had no response to a 16-week course of 
treatment with peginterferon alfa-2b and ribavi-
rin during the previous year. We enrolled him in 
an 18-month study of high-dose peginterferon 
alfa-2a (at a dose of 360 μg per week during the 
first 4 weeks) in combination with ribavirin (at 
a dose based on weight). The study enrolled pa-
tients with genotype 1, and the index patient 
was the second of nine patients to enroll. The 
study was approved by our institutional review 
board, and patients provided written informed 
consent. At the start of treatment, the index pa-
tient’s serum level of alanine aminotransferase 
was 106 IU per milliliter (normal, <41), and the 
serum level of HCV RNA was 6.8 log copies per 
milliliter.
To determine the effect of the administration 
of peginterferon alfa-2a on pharmacokinetic and 
plasma viral kinetic profiles, peginterferon alfa-
2a levels were measured with the use of a quan-
titative sandwich enzyme-linked immunosorbent 
assay (ELISA) for interferon alfa (Bender Med-
Systems Diagnostics GmbH), and HCV RNA levels 
were quantitated (Cobas Amplicor HCV test, 
Roche Diagnostics) at baseline and at days 1, 2, 
4, 7, 14, 21, and 28 after the start of treatment. 
We observed a variation in pharmacokinetic pro-
files among patients. In contrast to the other 
eight patients, the index patient’s levels of peg-
interferon alfa-2a were virtually undetectable, 
and he did not have any virologic response to 
treatment (Fig. 1A and 1B). This finding led us 
to measure the level of specific antibodies to in-
terferon alfa by ELISA. Interferon alfa–specific 
antibodies were detected at low levels before the 
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